We work with sponsors leading the renaissance in psychedelic clinical development to navigate the nuances of psychedelic trials, efficiently and effectively.
Worldwide Clinical Trials has helped sponsors like you develop psychedelic programs for the treatment of psychiatric illnesses since 2017. Our teams supported one of the first industry-sponsored, global studies in psychedelics, and have since supported numerous programs, applying emerging science to operationalize studies quickly and practically. We’ve mastered the complex operational delivery of working with controlled psychedelic compounds in psychiatric indications like major depressive disorder, treatment-resistant depression, post-traumatic stress disorder, substance use disorders, and anorexia nervosa.
Vice President, Neuroscience, Scientific Solutions
Christine Moore is an experimental psychologist by training with 25 years in drug development and commercialization at CROs and large and small pharma. Her experience extends from scientific to operational expertise with roles at the site level, in clinical monitoring and project management, through commercialization planning. She led a large rater training department within a CRO and has detailed knowledge of scales and assessments used in psychiatric trials. Involved with psychiatric clinical trials for many years, she has more recently focused on methodology and enhancing rigor in psychedelic clinical trials. Dr. Moore has also contributed to clinical development plans and written protocols for psychedelics, and is credited with peer-reviewed manuscripts and presentations in the psychedelic space.
Vice President of Clinical Projects, Clinical Assessment Technologies
Executive Director, Project Management
No two studies are alike—and we don’t treat them that way. We work with you to understand your study’s unique needs, leveraging our previous experience to guide us as we develop a new approach for you. We see every study as a collaboration, working together to advance your psychedelic program to new frontiers.
We understand and can help you overcome the challenges and risks associated with developing and commercializing a psychedelic with scalable treatment in mind.
Our in-house Clinical Assessment & Technologies team expertly select qualified independent efficacy raters and provide training across psychiatric indications, with careful attention in managing non-specific treatment effects and functional unblinding.
We’ve been a part of industry-sponsored psychedelic trials since they began. Our Psychedelic Center of Excellence has a comprehensive approach to the complex operational delivery of these trials and working with patients and sites for study success.
A crowded research space makes it difficult to weed the subjectivity out of the science—which demands a CRO with psychiatry know-how from the ground up and the top down. Our proven track record for patient recruitment and engaged investigator networks speaks volumes about our expertise in psychiatric trial development and execution.
Worldwide was founded to help improve research for neurology patients. Decades later, we’ve done it all, working on a dizzying number of compounds and indications in every phase. Now Worldwide is one of the few full-service CROs that provides integrated rater training, scale management, bespoke assessment development, and a broad range of other highly specialized consulting services in addition to our top-notch global network of study execution experts.
Our Cognitive Task Force and scale development work speak volumes about our commitment to Alzheimer’s and dementia research. At Worldwide, we design and execute rigorous, compassionate studies we’d be happy to have our own family and friends take part in, carefully protecting the patient experience and maintaining compelling data integrity to get products to market even in this competitive research space.
Rare neurological diseases each have unique hurdles for developing compelling outcomes assessments that can demonstrate efficacy with small patient populations. Worldwide is a leader in rare disease recruitment, novel endpoint development, and innovative study designs. We deliver specialty studies that apply our overarching knowledge in neurological conditions and rare diseases to thoughtful study designs, respecting patient communities and generating the data sponsors need to advance their compound to market.
Worldwide leads the way in best practice development for pain and addiction research. We have seen it all, which helps us offer the right blend of tried-and-true logistics, creative study designs, and thoughtful outcomes measures to augment objectivity in this otherwise nebulous field of research.